TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20683051

Group type: EXPERIMENTAL
Intervention: Sequential administration of cisplatin-etoposide followed by topotecan (arm A)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Alternate administration of cisplatin-etoposide and topotecan (arm B)
Number of subjects: 364
Study: 18434531

Group type: EXPERIMENTAL
Intervention: Low-serotonin condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-serotonin condition
Number of subjects: 0
Study: 16880023

Group type: EXPERIMENTAL
Intervention: Weak sense of coherence (SOC)
Number of subjects: 5866

Group type: EXPERIMENTAL
Intervention: Weak sense of coherence (SOC) in men aged >=55 years
Number of subjects: 5866

Group type: COMPARATOR
Intervention: Strong sense of coherence (SOC)
Number of subjects: 5866
Study: 14522530

Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD) with oral and enteral polymyxin E, tobramycin, and amphotericin B combined with an initial 4-day course of intravenous cefotaxime
Number of subjects: 934

Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 934

Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD)
Number of subjects: 934
Study: 11004613

Group type: COMPARATOR
Intervention: OKTcdr4a 225 mg/course (low dose)
Number of subjects: 28

Group type: COMPARATOR
Intervention: OKTcdr4a 750 mg/course (high dose)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: OKTcdr4a 750 mg/course (high dose) after initial treatment
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Placebo or low-dose OKTcdr4a followed by high-dose OKTcdr4a
Number of subjects: 28
Study: 9122545

Group type: EXPERIMENTAL
Intervention: Intact milk (240 or 360 mL)
Number of subjects: 960

Group type: COMPARATOR
Intervention: Hydrolyzed milk (240 or 360 mL)
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Lactose intolerance
Number of subjects: 960
Study: 1296499

Group type: EXPERIMENTAL
Intervention: ioversol 300 mg/ml
Number of subjects: 80

Group type: COMPARATOR
Intervention: iohexol 300 mg/ml
Number of subjects: 80
Study: 6691015

Group type: EXPERIMENTAL
Intervention: Weekly pelvic examinations starting at 37 weeks' gestation
Number of subjects: 349

Group type: COMPARATOR
Intervention: No pelvic examinations until term or past term
Number of subjects: 349
Study: 30639003

Group type: EXPERIMENTAL
Intervention: Moderate milk replacer (MOD)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High milk replacer (HI)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Neomycin-oxytetracycline inclusion (NTMOD)
Number of subjects: 48
Study: 29732651

Group type: EXPERIMENTAL
Intervention: 8 weekly 2‐hr workshop sessions
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: web‐based modules
Number of subjects: 144

Group type: COMPARATOR
Intervention: nonrandomised control group
Number of subjects: 144
Study: 26628615

Group type: EXPERIMENTAL
Intervention: External stenting
Number of subjects: 24

Group type: COMPARATOR
Intervention: No external stenting (unstented)
Number of subjects: 24
Study: 24594499

Group type: EXPERIMENTAL
Intervention: Promethazine 25 mg intravenously
Number of subjects: 184

Group type: COMPARATOR
Intervention: Lorazepam 2 mg intravenously
Number of subjects: 184
Study: 23149532

Group type: EXPERIMENTAL
Intervention: Vitamin D (150,000 IU vitamin D(3) orally)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Vitamin D (150,000 IU vitamin D(3) orally) over 12 weeks
Number of subjects: 84
Study: 20159180

Group type: EXPERIMENTAL
Intervention: ACIDFORM gel (plus diaphragm)
Number of subjects: 120

Group type: COMPARATOR
Intervention: K-Y Jelly (plus diaphragm)
Number of subjects: 120
Study: 17664498

Group type: EXPERIMENTAL
Intervention: Prevention Care Management (PCM)
Number of subjects: 1316

Group type: COMPARATOR
Intervention: Comparison group (modified mammography telephone outreach program)
Number of subjects: 1316
Study: 16109660

Group type: EXPERIMENTAL
Intervention: MRI examination technique
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional enteroclysis
Number of subjects: 36
Study: 11881521

Group type: EXPERIMENTAL
Intervention: Acamprosate 1332 to 1998 mg/day
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Acamprosate with psychosocial support (individual psychotherapy, group psychotherapy, behavioural therapy, brief intervention, family therapy)
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 753
Study: 11271401

Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg) prior to encoding
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg) at retrieval
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Different drug state (DS) conditions
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Same drug state (SS)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Different drug state (DS)
Number of subjects: 48
Study: 9298634

Group type: EXPERIMENTAL
Intervention: Propentofylline (300 mg, three times daily 1 hour before meals)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study: 8443935

Group type: EXPERIMENTAL
Intervention: Tretinoin emollient cream 0.01%
Number of subjects: 40
Study: 3816685

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31758177

Group type: EXPERIMENTAL
Intervention: LID/ΔM2‐2/1030s vaccine (105 PFU, intranasal)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 29518747

Group type: EXPERIMENTAL
Intervention: High-dose n-3 PUFA treatment (2 g/d)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 27736365

Group type: EXPERIMENTAL
Intervention: Ad-viewing condition
Number of subjects: 3258

Group type: COMPARATOR
Intervention: No-exposure control condition
Number of subjects: 3258
Study: 25277887

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study: 23598534

Group type: EXPERIMENTAL
Intervention: Colesevelam HCl (C-HCl)
Number of subjects: 21
Study: 20950329

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 541

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 541
Study: 18258627

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (100, 200, or 300 microg Se/d as high-selenium yeast)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Placebo yeast
Number of subjects: 501
Study: 16771810

Group type: EXPERIMENTAL
Intervention: CsA/Aza
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: CsA/MMF
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Tacr/Aza
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: CMV disease
Number of subjects: 84
Study: 12748513

Group type: EXPERIMENTAL
Intervention: Umbilical artery Doppler testing
Number of subjects: 1360

Group type: COMPARATOR
Intervention: Nonstress testing
Number of subjects: 1360
Study: 11074022

Group type: EXPERIMENTAL
Intervention: MEDLINE search strategies for detecting RCTs in prosthodontics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Publication type clinical trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Publication type randomized controlled trial
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combining search terms
Number of subjects: 0
Study: 8644642

Group type: EXPERIMENTAL
Intervention: Pirsidomine 10 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Pirsidomine 20 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Pirsidomine 40 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 1467291

Group type: EXPERIMENTAL
Intervention: TL‐01 lamps
Number of subjects: 15

Group type: COMPARATOR
Intervention: TL‐12 lamps
Number of subjects: 15
Study: 29764271

Group type: EXPERIMENTAL
Intervention: Intratympanic steroid injection (ITS)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Canalith repositioning procedure (CRP)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Vestibular suppressant (VS)
Number of subjects: 47
Study: 27881113

Group type: EXPERIMENTAL
Intervention: TAU + EFT (treatment as usual with integrated emotion-focused components)
Number of subjects: 130

Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: TAU + EFT
Number of subjects: 130

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 130
Study: 25319802

Group type: EXPERIMENTAL
Intervention: Acupuncture with manipulation
Number of subjects: 292

Group type: COMPARATOR
Intervention: Acupuncture without manipulation (sham control)
Number of subjects: 292
Study: 23457681

Group type: EXPERIMENTAL
Intervention: Interactive pain education (PE) program
Number of subjects: 131

Group type: COMPARATOR
Intervention: Interactive control program (general dementia education)
Number of subjects: 131
Study: 20190370

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minodronate
Number of subjects: 0
Study: 18165461

Group type: EXPERIMENTAL
Intervention: Zolpidem extended release 6.25 mg
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study: 16014796

Group type: EXPERIMENTAL
Intervention: Temporal pitch stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spatial width stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integration of pitch and spatial width
Number of subjects: 0
Study: 12970227

Group type: COMPARATOR
Intervention: Inhaled NO (20 ppm)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous sildenafil (1 mg/kg in 'cath laboratory', 0.25 mg/kg post op)
Number of subjects: 24
Study: 10391657

Group type: EXPERIMENTAL
Intervention: 20% of maximal workload on a cycle ergometer (mean load of 32 watts)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 60% of maximal workload on a cycle ergometer (mean load of 85 watts)
Number of subjects: 28
Study: 8675588

Group type: EXPERIMENTAL
Intervention: Ethanol 1.0 g/kg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ethanol 0.5 g/kg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (no ethanol)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Synthetic TRH (1 microgram/kg BW)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ethanol (any dose)
Number of subjects: 13
Study: 1706502

Group type: EXPERIMENTAL
Intervention: VVIR pacing (single setting rate responsive)
Number of subjects: 12

Group type: COMPARATOR
Intervention: VVI pacing (fixed rate demand)
Number of subjects: 12
Study: 6517563

Group type: EXPERIMENTAL
Intervention: Topical acyclovir treatment
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 30508308

Group type: EXPERIMENTAL
Intervention: D/C/F/TAF split tablet (800/150/200/10 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: D/C/F/TAF crushed tablet (800/150/200/10 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: D/C/F/TAF whole tablet (800/150/200/10 mg)
Number of subjects: 30
Study: 30089485

Group type: EXPERIMENTAL
Intervention: Continuous Quality Improvement (CQI) intervention applied at the cluster level with training and mentoring for staff.
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group receiving the South African Department of Health standard of care.
Number of subjects: 7
Study: 26923235

Group type: EXPERIMENTAL
Intervention: 12-week high-intensity interval and resistance training program (EXP group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual activities of daily living (CTL group)
Number of subjects: 40
Study: 24527443

Group type: EXPERIMENTAL
Intervention: Combination of alprazolam 0.5 mg and melatonin 3 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Alprazolam 0.5 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Melatonin 3 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 22880945

Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Micronutrient supplement
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Food and micronutrient groups
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Food group
Number of subjects: 217
Study: 21172109

Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate (HoLEP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard transurethral resection of the prostate (TURP)
Number of subjects: 80
Study: 16876559

Group type: EXPERIMENTAL
Intervention: Resistance training (twice a week for 16 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (medical therapy only)
Number of subjects: 16
Study: 12542428

Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment (ART) using hand instruments
Number of subjects: 403

Group type: COMPARATOR
Intervention: Rotary instruments (750 r.p.m.)
Number of subjects: 403
Study: 10804043

Group type: COMPARATOR
Intervention: Celecoxib 100 mg and 200 mg, Naproxen 500 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Celecoxib 200 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Celecoxib 25 to 400 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Celecoxib (100 to 400 mg twice daily) and Naproxen 500 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0
Study: 9115004

Group type: EXPERIMENTAL
Intervention: 750 micrograms of vaginal misoprostol after 50 mg/m2 methotrexate IM
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: 500 micrograms of vaginal misoprostol after 50 mg/m2 methotrexate IM
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Vaginal route for second dose of misoprostol after one dose failed
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Oral route for second dose of misoprostol after one dose failed
Number of subjects: 756

Group type: COMPARATOR
Intervention: 60 mg/m2 methotrexate
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Three vaginal doses of misoprostol 8 hr apart starting on Day 5
Number of subjects: 756

Group type: COMPARATOR
Intervention: One vaginal dose of misoprostol
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Overall medical abortion with methotrexate and misoprostol
Number of subjects: 756
Study: 8262821

Group type: EXPERIMENTAL
Intervention: Surgical resection leaving positive margins followed by postoperative adjuvant therapy (majority received postoperative radiotherapy +/- chemotherapy)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Surgical resection leaving positive margins followed by postoperative adjuvant therapy
Number of subjects: 109

Group type: COMPARATOR
Intervention: Definitive radiotherapy alone
Number of subjects: 109
Study: 3985390

Group type: EXPERIMENTAL
Intervention: Epidural administration of 1.5% lidocaine with 80 mg methylprednisolone (group II)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Epidural administration of preservative-free physiologic saline solution and 80 mg methylprednisolone (group I, control group)
Number of subjects: 19
Study: 31204181

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lateral position
Number of subjects: 60
Study: 28363320

Group type: EXPERIMENTAL
Intervention: buprenorphine-naloxone with varying duration and counseling of varying intensity
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: long-term follow-up
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: opioid agonist treatment at the time of follow-up
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: no agonist treatment
Number of subjects: 653
Study: 25527035

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg doses, four times daily, total daily dose of 800 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 23682075

Group type: EXPERIMENTAL
Intervention: Zileuton
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Zileuton and Celecoxib
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (Celecoxib alone)
Number of subjects: 52
Study: 21368390

Group type: EXPERIMENTAL
Intervention: Carnitine
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Combination of carnitine and coenzyme Q10
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 19484178

Group type: EXPERIMENTAL
Intervention: Tumescent solution containing lidocaine and epinephrine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Tumescent solution containing only epinephrine
Number of subjects: 70
Study: 17208005

Group type: EXPERIMENTAL
Intervention: Modern antiemetic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control of nausea
Number of subjects: 0
Study: 15200743

Group type: EXPERIMENTAL
Intervention: Milnacipran (100 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Imipramine (150 mg/day)
Number of subjects: 100
Study: 12165890

Group type: EXPERIMENTAL
Intervention: 4-min vibration intervention
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 16
Study: 9822139

Group type: EXPERIMENTAL
Intervention: Nitrendipine (with enalapril and hydrochlorothiazide if needed)
Number of subjects: 4695
Study: 7640122

Group type: EXPERIMENTAL
Intervention: Xenon
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 6
Study: 2787399

Group type: EXPERIMENTAL
Intervention: Treatment group (n = 53) with occlusal interferences eliminated annually
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (n = 46) undergoing placebo treatment
Number of subjects: 99
Study: 792853

Group type: EXPERIMENTAL
Intervention: Equine anti-human-lymphocyte globulin (ALG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 31124948

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 80
Study: 28181706

Group type: EXPERIMENTAL
Intervention: Midazolam + Fentanyl (MF group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Propofol + Fentanyl (PF group)
Number of subjects: 100
Study: 25656923

Group type: EXPERIMENTAL
Intervention: Nexö-method (test group24)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group24
Number of subjects: 200

Group type: COMPARATOR
Intervention: External control group24
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Nexö-method (test group28)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group28
Number of subjects: 200

Group type: COMPARATOR
Intervention: External control group28
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control groups24,28
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Test groups
Number of subjects: 200
Study: 23547047

Group type: EXPERIMENTAL
Intervention: Ethinylestradiol-cyproteroneacetate (EE-CA)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Low-dose combination of pioglitazone (7.5 mg/d), flutamide (62.5 mg/d), and metformin (850 mg/d) (PioFluMet)
Number of subjects: 34
Study: 21334736

Group type: EXPERIMENTAL
Intervention: Everolimus-based regimen (trough concentrations 6-10 ng/mL) with enteric-coated mycophenolate sodium (1440 mg/day) and corticosteroids
Number of subjects: 503

Group type: COMPARATOR
Intervention: Ciclosporin-based regimen
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Everolimus-based regimen
Number of subjects: 503
Study: 19500829

Group type: EXPERIMENTAL
Intervention: Youth-focused relationships education curriculum
Number of subjects: 0
Study: 16978576

Group type: EXPERIMENTAL
Intervention: 4 mg intravitreal triamcinolone acetonide
Number of subjects: 32

Group type: COMPARATOR
Intervention: 2 mg intravitreal triamcinolone acetonide
Number of subjects: 32
Study: 15106511

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 109
Study: 11708699

Group type: EXPERIMENTAL
Intervention: Low dose of Nortesten (72 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dose of Nortesten (144 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nortesten (both doses)
Number of subjects: 0
Study: 9146195

Group type: EXPERIMENTAL
Intervention: Oval-shaped cloth nest
Number of subjects: 102

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 102
Study: 8198156

Group type: EXPERIMENTAL
Intervention: Combined timolol 0.5% and pilocarpine 4%
Number of subjects: 43

Group type: COMPARATOR
Intervention: Pilocarpine 4%
Number of subjects: 43

Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 43
Study: 3136086

Group type: EXPERIMENTAL
Intervention: MCT/LCT emulsion
Number of subjects: 22

Group type: COMPARATOR
Intervention: LCT emulsion
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both emulsion types
Number of subjects: 22
Study: 31619205

Group type: EXPERIMENTAL
Intervention: Combined NRT (nicotine patch & gum)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Single NRT (nicotine patch)
Number of subjects: 560
Study: 28189292

Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray (32 IE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 25395709

Group type: EXPERIMENTAL
Intervention: Yoga training and exercises for 3 months, 8 sessions per month, 60 to 90 minutes each session, including Hatayoga, Pranayama, and Rajayoga.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no yoga training).
Number of subjects: 60
Study: 22542215

Group type: EXPERIMENTAL
Intervention: Neonatal resuscitation protocol (NRP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibiotics with facilitated referral (AFR)
Number of subjects: 0
Study: 20571437

Group type: EXPERIMENTAL
Intervention: Ziprasidone (80‐160 mg/d given twice a day, mean modal dose of 112 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ziprasidone (80‐120 mg/d given every day, mean modal dose of 96 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol (5‐20 mg/d, mean modal dose of 12 mg/d)
Number of subjects: 0
Study: 17919155

Group type: EXPERIMENTAL
Intervention: Group music therapy (n = 21)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (n = 16)
Number of subjects: 37